molecules of the month


oral D1 modulator

Ph. I candidate for neurological disorders

opt. against DDI w/ hepatocyte Cl assay

J. Med. Chem.

Eli Lilly and Company

oral D1 modulator - Eli Lilly and Company
3 mins read

Context. LY3154885 (Eli Lilly and Company) is an oral D1 modulator. Lilly recently completed several clinical trials with LY3154207 (mevidalen), the first D1 positive allosteric modulator (D1PAM) with published clinical data, in Parkinson’s disease (NCT02562768), sleep (NCT02603861), and lewy body dementia (LBD) (NCT03305809). In nonclinical studies, mevidalen was found to be mainly cleared by CYP3A4, creating a risk for it being a victim drug to DDIs when co-dosed with CYP3A4 inhibitors or inducers. LY3154885 was a backup compound to address this DDI risk, with metabolism shifted from CYP-mediated to predominantly UGT-mediated by changing the tertiary alcohol-bearing group to a pyrazole. The molecule was advanced to Ph. I, but terminated early due to a business decision. Mechanism of Action. The D1…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: